Table 2 First-line treatment and efficacy after SCLC transformation
First line therapy after transformation | Cases (n) | Median PFS (95%CI, m) | Median OS since diagnosed (95%CI, m) |
|---|---|---|---|
Platinum + etoposide | 46 | 3.0 m (2.05 to 3.95 m) | 42.7 m (31.61 to 53.79 m) |
Platinum + etoposide + TKI | 19 | 3.2 m (2.21 to 4.19 m) | 59.3 m |
Others | 21 | 5.0 m (3.42 to 6.58 m) | 37.0 m (24.45 to 49.55 m) |
Total | 86 | 4.0 m (3.43 to 4.57 m) | 40.0 m (33.97 to 46.03 m) |